Patent ID: 11970469
Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A compound of Formula Ih, Ii, Ij or Ik, or a salt or solvate thereof:, wherein,
R1 is selected from C1-6 alkoxy and NRpRq, wherein Rp and Rq are independently selected from hydrogen, C1-6 alkyl and C(O)C1-3alkyl;
R2 and R3 are independently selected from the group consisting of hydrogen, hydroxyl, halogen, CN, C1-6 haloalkyl, C1-6 haloalkoxy, O—C1-6 alkyl and C1-6 alkyl;
R4 is selected from hydrogen and C1-3 alkyl;
R5 is selected from the group consisting of hydrogen, hydroxyl, ═O, halogen, CN, C1-6 haloalkyl, C1-6 haloalkoxy, O—C1-6 alkyl, C1-6 alkyl and NRpRq;
R6 is selected from the group consisting of hydrogen, hydroxyl, halogen, C1-6 haloalkyl, C1-6 haloalkoxy, O—C1-6 alkyl, C1-6 alkyl and NRpRq;
R7a and R7b are independently selected from hydrogen, hydroxyl, halogen, C1-6 haloalkyl, C1-6 haloalkoxy, O—C1-6 alkyl and C1-6 alkyl;
R8 is selected from selected from the group consisting of hydrogen and C1-6 alkyl; and
R9 is selected from C1-6 alkyl, optionally substituted with one or more groups of HNMe or NMe2; or
R9 is —(CH2)1-6-heterocycle, wherein said heterocycle is or morpholine optionally substituted with one or more C1-6 alkyl; or
R9 if —C(O)NH(CH2)1-4-heterocycle, wherein said heterocycle is piperidine substituted by Rk; wherein Rk is selected from the group consisting of hydrogen, C1-6 alkyl optionally substituted with phenyl, —C(O)OH, and —C(O)OC1-6 alkyl.